

Availability of preparatory documents for the Combined General Meeting of May 31, 2016

Paris, April 27, 2016 – 18:00 PM – OSE Pharma SA (ISIN : FR0012127173 ; Mnémo : OSE), an immunology company developing a T-specific immunotherapy, currently in a registration Phase 3 study, announces the online publication of preparatory documents to the Combined General Meeting to be held on May 31, 2016 at 9:00 am at the Hotel Pershing, 49, rue Pierre Charron, 75008 Paris, are available on the company's website.

The meeting notice containing the agenda and the draft resolutions was published in the BALO of March 23 2016, and amended by a corrective notice published in the BALO on April 15, 2016. The corresponding convening notice will be published on May 13, 2016 in the BALO and in the *Journal Spécial des Sociétés* (a French journal of legal notices).

The preparatory documents for the General Meeting set out in Article R. 225-73-1 of the French Commercial Code are available on the Company's website (<http://osepharma.com/investisseurs/documentation/assemblee-generale>).

More specifically regarding the merger of Effimune by OSE Pharma, the merger document, constituting an annex to the report of the Board of OSE Pharma's report to the general meeting, was recorded by the AMF on April 26, 2016 under the number E.16-026, and is available on the website of the company and on the AMF website.

The preparatory documents for the General Meeting will be made available to shareholders from the date of the meeting notice. In accordance with applicable regulations:

- Each registered shareholder can, until the fifth day prior General Meeting, request the Company to send the documents referred in Articles R. 225-81 and R. 225-83 of the French Commercial Code, as appropriate to its express request, electronically. For registered holders, the exercise of this right is subject to the provision of a certificate of participation in the registered share accounts held by the authorized intermediary ;
- Any shareholder may consult the documents referred to in Articles L. 225-115 and R. 225-83 of the Commercial Code at the company headquarters (Pépinière Paris Santé Cochin – 29 bis, rue du Faubourg Saint-Jacques, 75014 Paris)

ABOUT OSE PHARMA

OSE Pharma is a biotechnology company that designs and develops cancer immunotherapy treatments aimed at re-educating the immune system to fight cancer while preserving patients' quality of life. The Company is conducting a Phase 3 registration trial in Europe and the U.S. for its lead product, Tedopi[®], in the treatment of NSCLC.

Tedopi® (OSE-2101) is a new “off-the-shelf” cancer immunotherapy approach based on OSE Pharma’s proprietary Memopi® technology. This technology is based on “neo-epitopes” (small synthetic peptides chemically modified to increase the binding the HLA A2 or TCR receptors) which activate a cytotoxic T-cell response and leads the immune system to destroy cancer cells. More than 10,000 epitopes were selected to obtain a therapeutic universal T vaccine.

Tedopi® combines 10 optimized “neo-epitopes” simultaneously acting against 5 tumor-associated antigens (TAAs). These 5 antigens have been selected because they are a factor of poor prognosis in several types of cancers. The 10 “neo-epitopes” have been selected and modified to enhance their binding to HLA-A2 and TCR receptors, and trigger a stronger cytotoxic T-cell response and lead the immune system to destroy cancer cells expressing the HLA-A2 antigen or one of the targeted cancer antigens.

The Phase 3 trial is based on Phase 2 results showing an immune T-cell response significantly correlated with a survival increase, as well as on the long term survival benefit observed in highly pretreated patients with a poor prognosis.

Tedopi® can also be developed in Phase 2 in combination with other immunotherapeutic products or targeted therapies. It is also considered for other oncology indications (ovary, colon, breast) for HLA-A2 positive patients.

OSE Pharma is listed on Euronext Paris (ISIN: FR0012127173; Mnemo: OSE).

For more information, please visit www.osepharma.com



 Follow us on Twitter @OSE_Pharma

For more information, please contact:

OSE Pharma SA

Dominique Costantini, CEO
dominique.costantini@osepharma.com
Mob +33 6 13 20 77 49

Alexis Peyroles, CFO & BD
Alexis.peyroles@osepharma.com
Mob : +33 6 11 51 19 77

Media contacts

Citigate Dewe Rogerson
Laurence Bault
laurence.bault@citigate.fr
+33 1 53 32 84 78

Alize RP

Florence Portejoie & Caroline Carmagnol
osepharma@alizerp.com
+33 6 47 38 90 04

Consilium Strategic Communications

Chris Gardner / Matthew Neal / Hendrik Thys
OSEPharma@consilium-comms.com
+44 (0) 20 3709 5700

Rx Communications Group, LLC

Melody Carey
mcarey@rxir.com
+ 1 917-322-2571

Disclaimer:

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE PHARMA. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and

assessments made by OSE PHARMA's management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. Forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE PHARMA's management believes that the forward-looking statements and information are reasonable, the OSE PHARMA's shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE PHARMA. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE PHARMA with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE PHARMA Reference Document filed with the AMF on 12 June 2015 under the number R.15-051 as well as the consolidated financial statements and the management report for the fiscal year 2015, available on the OSE PHARMA website. OSE PHARMA undertakes no obligation to update any forward-looking statements except what would be required by applicable laws and regulations.